Quris

OverviewSuggest Edit

Quris Technologies is a biotechnology company that provides a platform for clinical prediction. Its AI platform predicts which drug candidates work in humans. The company develops a machine-learning approach that generates data for classification algorithms by testing drugs on miniaturized patients-on-a-chip.
TypePrivate
Founded2020
HQTel Aviv-Yafo, IL
Websitequris.ai

Latest Updates

Employees (est.) (Jun 2022)26(+14%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Quris Office Locations

Quris has offices in Tel Aviv-Yafo and Boston
Tel Aviv-Yafo, IL (HQ)
Yigal Alon St 114
Boston, MA, US
38 Wareham St
Show all (2)

Quris Financials and Metrics

Summary Metrics

Founding Date

2020

Quris total Funding

$28 m

Quris latest funding size

$19 m

Time since last funding

5 months ago

Quris investors

Quris's latest funding round in January 2022 was reported to be $19 m. In total, Quris has raised $28 m
Show all financial metrics

Quris Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Quris Online and Social Media Presence

Embed Graph

Quris News and Updates

Merck KGaA, Darmstadt, Germany, Enters into Option Agreement with Quris on its BioAI Platform for Clinical Safety Prediction

BOSTON and TEL-AVIV, Israel, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Quris, an artificial intelligence (AI) innovator disrupting the pharmaceutical arena, today announced it has signed an agreement with Merck KGaA, Darmstadt, Germany, a leading science and technology company, allowing Merck KGaA, Darmst…

Quris Closes $28 Million in Seed Funding From Top Institutional Investors

Industry Strengthens Support for AI Innovator in Push to Close Essential Gaps in Drug Development as Company Prepares for Clinical Testing of the First Drug Developed via the Quris Platform Industry Strengthens Support for AI Innovator in Push to Close Essential Gaps in Drug Development as Company P…

Quris Closes $28 Million in Seed Funding From Top Institutional Investors

Quris, an artificial intelligence (AI) innovator disrupting the pharmaceutical arena, today announced the final close of $28 million in seed funding – inclusive of the initial $9 million announced late last year with the launch of Quris’ BioAI platform for clinical prediction. Led by Welltech Ventur…

Quris combines AI with ‘patient on a chip’ to speed drug development and reduce animal testing

The necessity of animal testing is a sad one for the process of drug discovery, but there’s seemingly no good alternative to mice, even though they’re not particularly accurate human analogues. Quris claims to have the first real option in its combination of AI with data from a “patient on a chip” t…

Quris Frequently Asked Questions

  • When was Quris founded?

    Quris was founded in 2020.

  • How many employees does Quris have?

    Quris has 26 employees.

  • Who are Quris competitors?

    Competitors of Quris include Nucleai, GV20 Oncotherapy and BioXcel.

  • Where is Quris headquarters?

    Quris headquarters is located at Yigal Alon St 114, Tel Aviv-Yafo.

  • Where are Quris offices?

    Quris has offices in Tel Aviv-Yafo and Boston.

  • How many offices does Quris have?

    Quris has 2 offices.